U.S. Capital Wealth Advisors LLC Increases Stake in Eli Lilly and Company

In a recent filing with the Securities and Exchange Commission, U.S. Capital Wealth Advisors LLC announced a 7.9% increase in its holdings of shares in Eli Lilly and Company (NYSE:LLY) for the third quarter. After acquiring an additional 631 shares during this period, the institutional investor now possesses a total of 8,620 shares of the pharmaceutical giant. At the conclusion of the latest quarter, these shares were valued at approximately $7,636,000.

Several other institutional investors have also adjusted their positions in Eli Lilly. For example, M&G Plc entered the scene by purchasing a new stake in Eli Lilly during the first quarter, with an investment amounting to around $8,896,000. Virtu Financial LLC similarly acquired a new stake valued at approximately $2,138,000 in the same quarter. Notable growth was seen with China Universal Asset Management Co. Ltd., which raised its holdings by 19.6% and owns 9,897 shares worth about $7,699,000 after adding 1,620 shares. Moreover, Mutual Advisors LLC notably increased its holdings by 404.8% in the first quarter, now owning 62,598 shares valued at $48,699,000 after acquiring 50,197 additional shares. Private Advisor Group LLC has also seen growth, boosting its position by 0.6% in the same quarter, resulting in ownership of 76,282 shares worth around $59,345,000. Collectively, hedge funds and institutional investors now control approximately 82.53% of the company’s stock.

Analysts Provide Insights on Eli Lilly's Performance

Recent analyst reports have been positive regarding Eli Lilly's shares. Cantor Fitzgerald reaffirmed an “overweight” rating, setting a target price of $885.00 on the stock as noted in their report on September 16th. Meanwhile, Truist Financial has elevated its target price from $1,000.00 to $1,033.00 while issuing a “buy” rating on October 10th. Citigroup initiated coverage on August 14th and provided a “buy” rating with a price target of $1,060.00. Also on August 16th, Guggenheim raised its target price from $884.00 to $1,030.00, supplying a “buy” rating. Berenberg Bank followed suit, increasing its price target from $1,000.00 to $1,050.00. Overall, three analysts recommend holding the stock, while 17 suggest buying it, with an average rating of “Moderate Buy” and a price target around $1,002.24 according to MarketBeat.

Eli Lilly's Financial Performance and Market Presence

As of Thursday, Eli Lilly's stock opened at $902.96, with a significant market capitalization totaling $858.18 billion. The company shows a PE ratio of 132.98 and a P/E/G ratio of 2.79, alongside a beta of 0.42. Over the past 50 days, the stock’s moving average stands at $921.12, while the 200-day average is at $860.74. The company recorded a 52-week low of $547.61 and a high of $972.53. The financial indicators reveal a quick ratio of 0.87, a current ratio of 1.11, and a debt-to-equity ratio of 1.74.

The latest quarterly earnings report was shared on August 8th, revealing earnings of $3.92 per share, which outperformed the consensus estimate of $2.64 by $1.28. The company's revenue for that quarter reached $11.30 billion, exceeding analysts’ predictions of $9.83 billion. Eli Lilly demonstrated a return on equity of 67.52% along with a net margin of 18.86%. Forecasts from analysts suggest that Eli Lilly will report earnings of 16.49 per share for the current fiscal year.

Overview of Eli Lilly and Company

Eli Lilly and Company is a global leader in discovering, developing, and marketing pharmaceuticals for human health. The company offers a wide range of products, including treatments for diabetes such as Basaglar, Humalog, and Trulicity, as well as obesity management solutions like Zepbound.

investment, stocks, finance, earnings, markets